Top-News
Pharmazeutika Schweiz

Obseva SA News

Aktie
WKN:  A3EELW ISIN:  CH1260041939 US-Symbol:  OBSEF
0,0001 $
+0,0001 $
+9.900,00%
06.06.24 17:33:22
Handeln Depot/Watchlist
Aktienanzahl *
84,50 Mio.
Marktkapitalisierung *
7,76 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 29.02.2024

Unternehmensmeldungen

20.04.23 - GlobeNewswire
ObsEva Announces Change of Central Securities Depositary
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
31.03.23 - GlobeNewswire
ObsEva Files Year End 2022 Financial Statements
ObsEva Files Year End 2022 Financial Statements
15.03.23 - GlobeNewswire
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
13.03.23 - GlobeNewswire
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
24.02.23 - GlobeNewswire
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
19.12.22 - GlobeNewswire
ObsEva Announces Dismissal of Moratorium Proceedings
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
14.12.22 - GlobeNewswire
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
09.12.22 - GlobeNewswire
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
01.12.22 - GlobeNewswire
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
22.11.22 - GlobeNewswire
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million The sale proceeds are ...
26.10.22 - GlobeNewswire
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $ 1 6.0 million savings expected from assignment of program contracts, ...
13.10.22 - GlobeNewswire
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
13.09.22 - GlobeNewswire
ObsEva Announces Progress on Restructuring Initiatives
$7.6 million annual savings expected via re duction -in-force currently underway $6.2 million savings expected from assignment of l egacy linzagolix program contracts to Kissei ...
22.08.22 - GlobeNewswire
ObsEva Receives Nasdaq Non-Compliance Notice
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
17.08.22 - GlobeNewswire
ObsEva Files Second Quarter 2022 Financial Statements
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
01.08.22 - GlobeNewswire
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – August 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) , a biopharmaceutical ...
29.07.22 - GlobeNewswire
ObsEva Announces Management Change
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
27.07.22 - GlobeNewswire
ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
27.07.22 - GlobeNewswire
ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
28.06.22 - GlobeNewswire
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Newssuche

Videos

06.06.24 +5,66%
Technical Trading: Erdgas nach Rücksetzer Long
Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »